Purdue Pharma reached a $125 million settlement with McKinsey & Co. resolving claims related to the consulting firm’s work on opioid marketing strategies.
The proposed deal would end potential litigation by Purdue’s estate against McKinsey, which advised the drugmaker for over a decade. The deal was filed on Wednesday in the US Bankruptcy Court for the Southern District of New York.
Purdue Pharma, which filed for Chapter 11 bankruptcy in 2019, has been blamed for fueling the nationwide opioid addiction crisis. McKinsey has faced scrutiny and litigation for its work in the prescription opioid space.
The funds would flow to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.